NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00910897,Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD),https://clinicaltrials.gov/study/NCT00910897,,UNKNOWN,"Primary objective:

* Compare the complete remission (CR) rates (i.e., the true CR, with negative immunofixation) achieved with either four courses of VD or four courses of VTD.

Secondary objectives:

* Compare the following parameters following 4 cycles of VD or VTD induction treatment:

  * CR rate+ very good partial remission (VGPR) rate
  * Overall remission rate (CR + VGPR + partial remission (PR) rate)
  * K/l light chain ratio in patients in CR.
  * Safety (quality of the sampled stem cells, extrahaematological and haematological toxicity: specially neurological toxicity, length of hospitalization).
* Compare the CR rate and the CR + VGPR rates after post-induction autologous stem cell transplantation (ASCT).",NO,Multiple Myeloma,DRUG: Velcade-Dexamethasone|DRUG: Velcade-Thalidomide-Dexamethasone,,,,Intergroupe Francophone du Myelome,,ALL,"ADULT, OLDER_ADULT",PHASE3,205,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IFM 2007-02|Eudract 2007-005204-40,2008-03,2009-08,,2009-06-01,,2009-06-01,"ANVERS Centrumziekenhuis, Anvers, Belgium|Anvers Uza, Anvers, Belgium|Bruxelles Erasme, Bruxelles, Belgium|Bruxelles I Bordet, Bruxelles, Belgium|BRUXELLES St LUC, Bruxelles, Belgium|GILLY, Gilly, Belgium|YVOIR MontGodinne, Yvoir, Belgium|Chu Angers, Angers, France|CH Annecy, Annecy, France|Ch Avignon, Avignon, France|CH Bayonne, Bayonne, France|Chu Besancon, Besancon, France|CH BLOIS, Blois, France|Bobigny Avicenne, Bobigny, France|Chu Bordeaux, Bordeaux, France|Chu Brest, Brest, France|Caen M Interne Baclèse, Caen, France|CH Chartres, Chartres, France|Clamart Percy, Clamart, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|Chu Dijon, Dijon, France|Ch Dunkerque, Dunkerque, France|Chu Grenoble, Grenoble, France|CH La Roche Sur Yon, La Roche Sur Yon, France|Le Mans Victor Hugo, Le Mans, France|Chru Lille, Lille, France|Ch Lorient, Lorient, France|CHU Lyon Edouard Herriot, Lyon, France|CHU Lyon Sud Pierre Benite, Lyon, France|Lyon Léon Berard, Lyon, France|Marseille IPC, Marseille, France|CHR Metz Bonsecours, Metz, France|Chu Nancy, Nancy, France|Chu Nantes, Nantes, France|Nantes Catherine De Sienne, Nantes, France|CHU Nice M Interne, Nice, France|CHR Orléans, Orleans, France|Paris Cochin, Paris, France|Paris Hôtel Dieu, Paris, France|Paris Necker, Paris, France|Paris St Antoine, Paris, France|Paris St Louis, Paris, France|CHU Poitiers hemato, Poitiers, France|CHU Reims, Reims, France|CHU Rennes Hemato, Rennes, France|CHU Rennes M interne, Rennes, France|CH Roanne, Roanne, France|Rouen Becquerel, Rouen, France|CH St Brieuc, St Brieuc, France|St ETIENNE, St ETIENNE, France|CHRU Strasbourg, Strasbourg, France|Chu Toulouse, Toulouse, France|CHU Tours, Tours, France|CH Valence, Valence, France|CH Vannes, Vannes, France",
